Recombinetics (RCI), the St. Paul-based, animal-science and biotechnology firm, has completed an $11 million round of equity fundraising, resulting in a total of $24 million from individual investors since 2008.
The company, which is moving from research to commercialization, has hired Capitol Peak Asset Management of Washington, D.C., to assist in raising the next round of equity capital from institutional sources, which could top what already has been garnered.
"We have years of good science being done here, the products and the capability," said CEO Ian Friendly, who joined RCI this year from an executive post at General Mills. "We are on the launchpad."
Recombinetics also was the winner last week in the agriculture-food category of the annual Tekne Awards of the Minnesota High Tech Association. The high-tech competition judges lauded RCI for being "the premier gene-editing company in livestock, with applications in therapeutic development and testing, and in animal breeding and care."
RCI, with 35 employees, develops "precise swine models" of human diseases, including neurodegenerative diseases, heart disease, diabetes and cancer. It also creates hornless cows that cause fewer injuries to other animals and handlers and meatier cattle that are more tolerant to heat.
"We're currently selling pigs that have been engineered to replicate human disease states … to medical researchers," Friendly said. "The field in the future will be medical device companies, drug companies and other researchers.
"We will also in the next year commence with agricultural sales, introducing desirable traits into livestock. There will be a series of them. This is no difference from traditional breeding, and consumption is safe. We're going through the government process now. We can sell for research, but need regulatory approval to sell for consumption."
The company notes that gene-editing to magnify or lessen a trait is different from more controversial genetic modification.